Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rilan Bai

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Frontiers in Oncology|August 28, 2020
Mechanisms of Cancer Resistance to ImmunotherapyRilan Bai, Naifei Chen, Lingyu Li, et al.
Journal of Oncology|July 23, 2020
Precision Detection Technology: Equipping Precision Oncology with WingsRilan Bai, Zheng Lv, Xiao Chen, et al.
Frontiers in Oncology|July 29, 2021
Single Nucleotide Polymorphisms in <i>HOTAIR</i> Are Related to Breast Cancer Risk and Prognosis in the Northeastern Chinese PopulationZheng Lv, Changgui Kou, Naifei Chen, et al.
Asia-Pacific Journal of Clinical Oncology|January 21, 2020
Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastasesWenqian Li, Rilan Bai, Lei Qian, et al.
Journal of Oncology|August 2, 2021
Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint InhibitorsRilan Bai, Lingyu Li, Xiao Chen, et al.
Biomarker Research|June 9, 2026
Tumor-enriched circRNA TAFCR1 drives cancer progression and metastasis by disrupting UBE1-dependent TRIM21-mediated CD44 ubiquitinationRilan Bai, Yan Li, Lei Zhou, et al.
Cancer Biology & Medicine|July 14, 2021
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse eventsRilan Bai, Naifei Chen, Xiao Chen, et al.
Medicine|July 5, 2024
Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trialsYiqian Liu, Liyun Miao, Xiao Chen, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Frontiers in Oncology|August 28, 2020
Mechanisms of Cancer Resistance to ImmunotherapyRilan Bai, Naifei Chen, Lingyu Li, et al.
Journal of Oncology|July 23, 2020
Precision Detection Technology: Equipping Precision Oncology with WingsRilan Bai, Zheng Lv, Xiao Chen, et al.
Frontiers in Oncology|July 29, 2021
Single Nucleotide Polymorphisms in <i>HOTAIR</i> Are Related to Breast Cancer Risk and Prognosis in the Northeastern Chinese PopulationZheng Lv, Changgui Kou, Naifei Chen, et al.
Asia-Pacific Journal of Clinical Oncology|January 21, 2020
Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastasesWenqian Li, Rilan Bai, Lei Qian, et al.
Journal of Oncology|August 2, 2021
Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint InhibitorsRilan Bai, Lingyu Li, Xiao Chen, et al.
Biomarker Research|June 9, 2026
Tumor-enriched circRNA TAFCR1 drives cancer progression and metastasis by disrupting UBE1-dependent TRIM21-mediated CD44 ubiquitinationRilan Bai, Yan Li, Lei Zhou, et al.
Cancer Biology & Medicine|July 14, 2021
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse eventsRilan Bai, Naifei Chen, Xiao Chen, et al.
Medicine|July 5, 2024
Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trialsYiqian Liu, Liyun Miao, Xiao Chen, et al.
Pageof 3